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Abstract: Several autoantibodies directed against cardiac cellular proteins including G-protein-linked receptors, contrac-
tile proteins and mitochondrial proteins, have been identified in patients with dilated cardiomyopathy (DCM). Among 
these autoantibodies, anti-1-adrenoreceptor (AR) antibodies have long been discussed in terms of their pathogenetic role 
in DCM. Anti-1-AR antibody-positive patients with DCM showed significant deterioration of NYHA functional class as 
well as reduced cardiac function compared to those in autoantibody-negative patients. Various studies with a limited 
number of patients indicate that the use of immunoadsorption to eliminate immunoglobulin G (IgG) significantly im-
proves cardiac performance and clinical status in heart failure patients. Since removal of autoantibodies of the IgG3 sub-
class induces hemodynamic improvement and an increase in the left ventricular ejection fraction, antibodies belonging to 
IgG3 such as anti-1-AR antibodies might play an important role in reducing cardiac function in patients with DCM. Ac-
cording to a recent report, however, the effect of hemodynamic improvement by immunoadsorption threapy was similar 
among patients who were positive and negative for anti-1-AR antibodies, indicating that the beneficial effects of immu-
noadsorption might be not directly associated with the selective elimination of the 1-AR autoantibodies. Immunoadsorp-
tion therapy is a new therapeutic option for patients with DCM and heart failure, but further investigations are required to 
elucidate the specific antigens of cardiac autoantibodies responsible for the hemodynamic effects.  
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INTRODUCTION 
  Dilated cardiomyopathy (DCM) is a progressive myocar-
dial disease characterized by contractile dysfunction and 
ventricular dilatation. DCM is not a rare cause of congestive 
heart failure and the leading reason for heart transplantation 
world wide [1]. Although many different pathogenetic 
mechanisms and therapeutic treatments have been discussed, 
the ultimate answers to these questions are still lacking. 
AUTOANTIBODIES IN DCM PATIENTS 
  A variety of experimental studies suggest that alterations 
of the immune system might be involved in the pathogenesis 
of DCM [2]. A number of antibodies against various cardiac 
proteins have been identified in DCM, which can be divided 
into sarcolemmal proteins (e.g. myosin, actin, troponin and 
tropomyosin), mitochondrial enzymes (e.g. the ADP-ATP 
carrier, nicotinamide adenine dinucleotide dehydrogenase, 
ubiquinol-cytochrome-c reductase, lipoamide dehydrogenase 
andpyruvatedehydrogenase),heat-shockproteins(e.g. hsp70, 
hsp60and hsc70) and surface receptors (e.g. 1-adrenorecep-
tors (AR) and muscarinic receptors [3-8]. Among these, the 
pathogenetic role of autoantibodies against 1-AR has been 
well investigated in experimental models [9-11] and human 
DCM [12-14]. The 1-AR is a 7-transmembarane G-protein-
coupled receptor abundantly expressed on cardiomyocytes.  
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Catecholamine binding to the 1-AR transmits an intracellu-
lar signal through a cAMP-dependent protein kinase A 
pathway that drives functional alterations in cardiomyocyte 
contractility.  
  Previously, Wallukat and his colleagues observed the 
immunoglobulin G (IgG) fraction in sera from DCM patients 
could induce a positive chronotropic effect on neonatal rat 
cardiac myocytes [15]. That effect was inhibited by the 1-
blocking agent bisoprolol. It has also been reported that up to 
33% of patients with DCM produce detectable circulating 
autoantibodies directed against epitope regions of the 1-AR
[16], which bind to the second extracellular loop of 1-AR
and cause a sustained stimulation of the cAMP-dependent 
protein kinase A pathway, and are finally associated with 
reduced cardiac function in those patients [13]. The patho-
genic potential of 1-AR-specific autoantibodies was af-
firmed by recent studies in which recipient rodents devel-
oped DCM after passive transfer of 1-AR-specific antisera 
[17]. Jane-wit et al. [18] also reported that sustained agonism 
by 1-AR autoantibodies elicited caspase-3 activation, car-
diomyocyte apoptosis, and DCM in vivo.
  An extremely high incidence of anti-1-AR autoantibod-
ies is also reported in end-stage DCM patients who require 
mechanical cardiac support [12]. In selective patients in 
whom cardiac function can be normalized by mechanical 
cardiac support, a gradual disappearance of autoantibodies 
accompanies the recovery. Other clinical evidence have 
documented that the presence of these autoantibodies is 
closely related to serious ventricular arrhythmias [19,20] and 
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[21]. We screened for anti-1-AR autoantibodies against the 
second extracellular loop of human 1-AR in 52 patients 
with chronic heart failure, and found that the mean values of 
autoantibodies in those patients were significantly higher 
than those in normal control subjects (Fig. 1) [22]. Further-
more, during a follow-up of 3 years, patients with cardiac 
events had high anti-1-AR autoantibody titers compared 
with patients without cardiac events. Thus, measurements of 
the 1-AR autoantibodies are important and useful for the 
management of chronic heart failure patients. 
Fig. (1). Comparison of plasma anti-1-AR autoantibody levels in 
patients with chronic heart failure and control subjects.
IMMUNOADSORPTION THERAPY 
 Removal  of  1-AR autoantibodies with immunoadsorp-
tion (IA) is achieved by passing a patient’s plasma over col-
umns that remove immunoglobulins (Fig. 2). This IA for 
patients with DCM was first reported in an uncontrolled pilot 
study by Wallukat et al. [23], who showed that this tech-
nique efficiently removed circulating antibodies directed 
against the 1-AR. They also observed an improvement in 
NYHA functional class in those patients. That study was 
followed by other pilot studies that reported an improvement 
in short- and long-term hemodynamic effects in patients with 
heart failure, who were refractory to conventional medical 
therapy [24-26]. Dorffel et al. [24] performed IA on nine 
patients with DCM, left ventricular ejection fraction (LVEF) 
<25% on 5 consecutive days. During therapy, hemodynamic 
parameters were monitored with a Swan-Ganz thermodilu-
tion catheter. In those patients, a significant increase in car-
diac output (from 3.7±0.8 to 5.5±1.8 L/min; p<0.01) and a 
significant decrease in mean arterial pressure and mean pul-
monary arterial pressure was noted. Felix et al. [25] random-
ized 25 patients with DCM, LVEF<30% with evidence of 
1-AR autoantibody to IA therapy vs. conventional therapy. 
The treatment group underwent monthly IA followed by 
immunoglobulin substitution for 3 months. IA therapy led to 
a significant decrease in 1-AR autoantibody levels. The 
increase in LVEF and improvement of NYHA class were 
significantly greater in the treatment group compared with 
those in the control group. Muller et al. [26] evaluated 34 
patients with DCM with NYHA class II-IV, LVEF<29%, 
and evidence of elevated levels of 1-AR autoantibodies. 
The active treatment group of 17 patients underwent IA on 5 
consecutive days. At 1 year, the treatment group experienced 
a significant increase in LVEF (0.22 to 0.38, p=0.0001) and 
improvement in NYHA class compared with no significant 
changes in LVEF in the control group. Staudt et al. [27] 
studied the effect of IA on plasma nt-BNP and nt-ANP levels 
in15patientsdemonstratingsevereheartfailure (LVEF<35%) 
due to DCM. Four courses of IA therapy were performed at 
monthly intervals until month 3. Three months after IA, pa-
tients demonstrated significant improvement in LVEF, re-
duction in left ventricular dimension and plasma nt-BNP 
levels. Those single-center, case-control studies suggested 
that IA therapy could improve NYHA class and LVEF in 
subjects with chronic DCM and heart failure.  
Fig. (2). Immunoadsorption using the Immusorba column.
  Previous studies used a variety of IA methods including 
specific anti-1-AR antibody binding peptide columns (Co-
raffin, Affina Immuntechnik) [28], nonspecific sheep anti-
human IgG columns (Ig-Therasorb, Plasmaselect) [29], or 
staphylococcal protein A-agarose columns (Immunosorba,
Fresenius HemoCare). The anti-1-AR autoantibodies are 
included in IgG3, and Staudt et al. [30] reported a signifi-
cantly improved cardiac index and LVEF for patients with 
DCM treated by IA with an anti-IgG column that removed 
significantly more IgG3 (89±3%) than in patients with DCM 
treated by IA with a protein A column that removed only 
37±4% of IgG3. The protein A group did not achieve a sig-
nificant increase in cardiac index or LVEF. Follow-up study 
of that series showed that IA with protein A columns with 
the addition of an improved treatment regime for IgG3 
elimination could induce hemodynamic improvement in 
DCM patients [31]. Those studies indicated that the removal 
of IgG3 is essential to achieve therapeutic effects of IA to 
DCM. We have used tryptophan columns (ImmusorbaTR,
Asahi Kase Kuraray Medical) that contain cross-linked poly-
vinyl alcohol gel beads as the matrix to which the hydropho-
bic amino acid tryptophan is immobilized (Fig. 2). It pos-
sesses nonselective physical features, but causes marked 
reduction of plasma levels of IgG3. In our protocol, plasma 
IgG and IgG3 levels dropped an average of 37% and 58% 
per single IA procedure, respectively. 
  Usually IA was followed by intravenous immunoglobulin 
(IVIG) to prevent infectious complications that might arise 
from inappropriate lowering circulating IgG levels [25]. Un-
like most previous studies, however, Cooper et al. [32] did 
not substitute IVIG following IA for DCM patients to con-
firm the effect of IA. This was because IVIG at high doses 
can affect left ventricular function in chronic DCM [33], and 
has been associated with a significant rate of adverse events 
in subjects with autoimmune diseases [34]. They found that, 
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was associated with a significant improvement in the quality 
of life for up to 6 months after treatment. Global wall mo-
tion, as assessed by two-dimensional strain echocardiogra-
phy, also showed a tendency towards improvement at 6 
months.  
  Although IA is a new therapeutic option for patients with 
DCM, the mechanism of left ventricular functional benefit 
from IA is not known. IgG adsorption removes not only anti-
1-AR-autoantibodies but also all other potentially patho-
genic autoantibodies affecting the heart in this class of im-
munoglobulins. Mobini et al. [35] has reported that the effect 
of hemodynamic improvement during IA was similar among 
patients positive and negative for 1-AR autoantibodies. 
Their results suggest that the beneficial effects of IA are not 
directly associated with the selective elimination of 1-AR
autoantibodies [36]. Schimke et al. [37] reported that a de-
crease in oxidative stress may be functionally important. In 
their study, three measures of oxidative stress, thiobarbituric 
acid-reactive substances, lipid peroxides, and antioxidized 
low density lipoprotein antibodies decreased significantly 
one year after selective IA of anti-1-AR-autoantibodies 
with improvement of cardiac performance.  
FUTURE DIRECTIONS 
  According to previous reports, the following questions 
remain to be resolved [38]: First, it will be important to iden-
tify the subsets of patients with DCM that will benefit the 
most from IA therapy, or determine whether patients with 
elevated levels of circulating autoantibodies (e.g., anti-1-
AR autoantibodies) should be studied. Second, the mecha-
nism(s) underlying the action of IA have not yet been identi-
fied. Although studies have demonstrated decreases in circu-
lating autoantibodies, it is not at all clear that a cause-and-
effect relationship has been established. Third, the optimal 
strategy for IA has yet to be determined. Different investiga-
tors use different protocols and different immunoadsorbent 
devices. Moreover, the use of IVIG replacement in some of 
the IA protocols may improve the clinical status of patients 
with DCM [39], rather than neutralization of 1-AR autoan-
tibodies. Finally, it is not clear from existing studies whether 
IA alone, which would be expected to modulate humoral 
immunity, will be sufficient over the long term, or whether it 
may be necessary to incorporate strategies that lead to sup-
pression of cellular-mediated immunity as well. It is time to 
consider performing randomized clinical trials with IA in 
order to answer these questions. 
CONCLUSION 
 Measurements  of  anti-1-AR autoantibodies may be 
helpful for the monitoring of clinical status in patients with 
DCM. IA therapy to eliminate autoantibodies is a new and 
promising therapeutic option for those patients. However, 
further studies are necessary to elucidate the specific anti-
gens of cardiac autoantibodies as well as cellular mecha-
nisms responsible for the observed functional effects.  
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